Edwards LifesciencesEW +3.12%97 Days Payable is 51.41 as of Mar. 2026, which is 12% below its 10-year median of 58.36. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.17 (Fairly Valued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 68.18% on this metric.
The historical rank and industry rank for Edwards Lifesciences's Days Payable or its related term are showing as below:
EW'
s Days Payable Range Over the Past 10 Years
Min: 36.85 Med: 58.36 Max: 102.48
Current: 47.51
During the past 13 years, Edwards Lifesciences's highest Days Payable was 102.48. The lowest was 36.85. And the median was 58.36.
EW's Days Payable is ranked worse than 68.18% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs EW: 47.51
Edwards Lifesciences's Days Payable
declined
from Mar. 2025 (55.94) to Mar. 2026 (51.41).
It may suggest that Edwards Lifesciencesaccelerated paying its suppliers.
Edwards Lifesciences Days Payable Related Terms
Edwards Lifesciences Days Payable Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Edwards Lifesciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Edwards Lifesciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (EW) has a Days Payable of 51.41 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Edwards Lifesciences and its competitors. This is 12% below median its historical median of 58.36. Over the past decade, Edwards Lifesciences' Days Payable has ranged from 36.85 to 102.48. According to the industry distribution chart, Edwards Lifesciences ranks #542 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 68.2%.
Is Edwards Lifesciences' Days Payable too high?
Edwards Lifesciences' current Days Payable of 51.41 is 12% below median its 10-year median of 58.36. Over the past 10 years, this metric has ranged from a low of 36.85 to a high of 102.48. The Medical Devices & Instruments industry median Days Payable is 67.87. Edwards Lifesciences' value of 51.41 is 24.3% below this industry median. Based on the distribution chart, Edwards Lifesciences ranks #542 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Days Payable compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #542 out of 795 companies for Days Payable. This places Edwards Lifesciences in the lower half of its industry. The industry median Days Payable is 67.87. Edwards Lifesciences' value of 51.41 is 24.3% below this benchmark. Historically, Edwards Lifesciences' own Days Payable has ranged from 36.85 to 102.48 over the past decade. While the company's 10-year median is 58.36 vs. the industry median of 67.87, Edwards Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current Days Payable of 51.41 is 24.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current Days Payable is 51.41, which is 12% below median its own 10-year median of 58.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.17, compared to a current price of $89.66 — trading 3.8% below its estimated fair value. The current Days Payable is 51.41, which is 12% below median its 10-year median of 58.36 and 24.3% below the Medical Devices & Instruments industry median of 67.87. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current Days Payable is 51.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of $89.66 is trading 3.8% below its estimated GF Value™ of $93.17.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for EW:
Days Payable: 51.41 (12% below median its 10-year median of 58.36)
GF Value™: $93.17 vs. price of $89.66 (3.8% below fair value)
Industry Position: 24.3% below the Medical Devices & Instruments median (#542 of 795)
No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for EW
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EW has been successfully added to your 
